

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>DigitalX Limited</b>
<b>ABN</b>	<b>59 009 575 035</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Peter Irwin Rubinstein
<b>Date of last notice</b>	21 May 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Irwin Biotech Nominees Pty Ltd ATF BIOA Trust. Peter Irwin Rubinstein is the sole director and shareholder of Irwin Biotech Nominees Pty Ltd and sole member of PIR Super Fund BIOA Trust
<b>Date of change</b>	(1) 23 December 2022 (2) 22 December 2022

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. of securities held prior to change</b>	<p><b>Direct</b>  617,284 Fully Paid Ordinary Shares</p> <p><b>Indirect</b>  16,196,296 Fully Paid Ordinary Shares<sup>1</sup>  8,626,348 Fully Paid Ordinary Shares<sup>2</sup>  3,694,444 Fully Paid Ordinary Shares<sup>3</sup>  7,200,000 Fully Paid Ordinary Shares<sup>4</sup>  1,000,000 Unlisted Options exercisable at \$0.22 each on or before 10 December 2023<sup>1</sup>  1,500,000 Unlisted Options exercisable at \$0.25 each on or before 10 December 2023<sup>1</sup>  2,000,000 Unlisted Options exercisable at \$0.30 each on or before the date 10 December 2023<sup>1</sup></p> <p>1. Held by Irwin Biotech Nominees Pty Ltd.  2. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust  3. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund  4. Held by ValueAdmin.Com Pty Ltd</p>
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	(1) 1,000,000 Fully Paid Ordinary Shares
<b>Number disposed</b>	(2) 138,768 Fully Paid Ordinary Shares
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>(1) \$26,100.10  (2) \$3,607.97</p>

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<p><b>Direct</b> 617,284 Fully Paid Ordinary Shares</p> <p><b>Indirect</b> 16,196,296 Fully Paid Ordinary Shares<sup>1</sup>  9,487,580 Fully Paid Ordinary Shares<sup>2</sup>  3,694,444 Fully Paid Ordinary Shares<sup>3</sup>  7,200,000 Fully Paid Ordinary Shares<sup>4</sup>  1,000,000 Unlisted Options exercisable at \$0.22 each on or before 10 December 2023<sup>1</sup> 1,500,000 Unlisted Options exercisable at \$0.25 each on or before 10 December 2023<sup>1</sup> 2,000,000 Unlisted Options exercisable at \$0.30 each on or before the date 10 December 2023<sup>1</sup></p> <p>1. Held by Irwin Biotech Nominees Pty Ltd.  2. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust  3. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund  4. Held by ValueAdmin.Com Pty Ltd</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>(1) On market purchase (2) On market sale</p>

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.